Prospective blinded Evaluation of the smartphone-based AliveCor Kardia ECG monitor for Atrial Fibrillation detection: The PEAK-AF study

Published:December 02, 2019DOI:


      • The AliveCor Kardia allows for a highly accurate rhythm diagnosis.
      • A novel parasternal lead adds valuable diagnostic information.
      • Recordings should be reviewed by an experienced cardiologist.



      The AliveCor Kardia ECG monitor (ACK) offers a smartphone-based one-lead ECG recording for the detection of atrial fibrillation. We compared ACK lead I recordings with the 12-lead ECG and introduce a novel parasternal lead (NPL).


      Consecutive cardiac inpatients were recruited. In all patients a 12-lead ECG, ACK lead I and NPL were obtained. Two experienced electrophysiologists were blinded and separately evaluated all ECG. We calculated sensitivity, specificity, and predictive values of the ACK ECG compared to the 12-lead ECG.


      296 ECG from 99 patients (38 female, age 64 ± 15 years, BMI 27.8 ± 5.1 kg/m2) were analyzed. 20% of ACK lead I recordings contained a critical amount of artifact. The electrophysiologists’ interpretation of the ACK recordings yielded a sensitivity of 100% and specificity of 94% for atrial fibrillation or flutter in lead I (κ = 0.90) and a sensitivity of 96% and specificity of 97% in the NPL (κ = 0.92). The ACK diagnostic algorithm displayed a significantly lower sensitivity (55–70%), specificity (60–69%), and accuracy (κ = 0.4–0.53) but a high negative predictive value (100%). Patients with atrial flutter (n = 5) and with ventricular stimulation (n = 12) had a high likelihood of being misclassified by the algorithm.


      The AliveCor Kardia ECG monitor allows a highly accurate detection of atrial fibrillation by an interpreting electrophysiologist both in the standard lead I and a novel parasternal lead. The diagnostic algorithm offered by the system may be useful in screening recordings for further review. Diagnostic challenges present in atrial flutter and ventricular pacemaker stimulation.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Lin H.J.
        • Wolf P.A.
        • Kelly-Hayes M.
        • et al.
        Stroke severity in atrial fibrillation. The Framingham Study.
        Stroke. 1996; 27 (PubMed PMID: 8841325): 1760-1764
        • Lozano R.
        • Naghavi M.
        • Foreman K.
        • et al.
        Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010.
        Lancet. 2012; 380 (PubMed PMID:23245604): 2095-2128
        • Kirchhof P.
        • Benussi S.
        • Kotecha D.
        • et al.
        ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.
        Eur Heart J. 2016; 37 (PubMed PMID:27567408): 2893-2962
        • Turakhia M.P.
        • Desai M.
        • Hedlin H.
        • et al.
        Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: the Apple Heart Study.
        Am Heart J. 2019; 207 (PubMed PMID:30392584): 66-75
        • Freedman B.
        • Camm J.
        • Calkins H.
        • et al.
        Screening for atrial fibrillation: a report of the AF-screen international collaboration.
        Circulation. 2017; 135 (PubMed PMID:28483832): 1851-1867
        • Mairesse G.H.
        • Moran P.
        • Van Gelder I.C.
        • et al.
        Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana De Estimulacion Cardiaca y Electrofisiologia (SOLAECE).
        Europace. 2017; 19 (PubMed PMID:29048522): 1589-1623
      1. US Food and Drug Administration. 510(k) Premarket Notification 2014 [updated 29.04.201906.05.2019]. Available from:

        • William A.D.
        • Kanbour M.
        • Callahan T.
        • et al.
        Assessing the accuracy of an automated atrial fibrillation detection algorithm using smartphone technology: the iREAD study.
        Heart Rhythm. 2018; 15 (PubMed PMID:30143448): 1561-1565
        • Viera A.J.
        • Garrett J.M
        Understanding interobserver agreement: the kappa statistic.
        Fam Med. 2005; 37 (PubMed PMID:15883903): 360-363
        • Lowres N.
        • Neubeck L.
        • Salkeld G.
        • et al.
        Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study.
        Thromb Haemost. 2014; 111 (PubMed PMID:24687081): 1167-1176
        • Chan P.H.
        • Wong C.K.
        • Pun L.
        • et al.
        Head-to-Head comparison of the AliveCor heart monitor and microlife watchbp office AFIB for atrial fibrillation screening in a primary care setting.
        Circulation. 2017; 135 (PubMed PMID:28028066): 110-112